We are live on ! Find out more
XGN icon

Exagen
XGN

30 hedge funds and large institutions have $13.1M invested in Exagen in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

3% more funds holding

Funds holding: 29 → 30 (+1)

2.05% less ownership

Funds ownership: 40.72% → 38.67% (-2%)

21% less capital invested

Capital invested by funds: $16.7M → $13.1M (-$3.55M)

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
11
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
+$424K
2
CAC
Cowen and Company
New York
+$97.3K
3
Renaissance Technologies
Renaissance Technologies
New York
+$78.7K
4
Citadel Advisors
Citadel Advisors
Florida
+$35.9K
5
RI
RTW Investments
New York
+$21K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$923K
2
UBS Group
UBS Group
Switzerland
-$118K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$31.8K
4
NCM
Nantahala Capital Management
Connecticut
-$16.7K
5
BlackRock
BlackRock
New York
-$16K

XGN Hedge Fund Activity: Q4 2023 in Review

30 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q4 2023, worth a combined $13.1M — down 21% from $16.7M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new XGN positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 11 trimmed.

The largest buyer was Perkins Capital Management, adding an estimated $424K. The largest seller was Stonepine Capital Management, cutting an estimated $923K.

  • 30 institutional investors held Exagen (XGN) as of Q4 2023, up from 29 in Q3 2023.
  • Funds reported $13.1M of Exagen stock for Q4 2023, down 21% quarter-over-quarter.
  • 3 funds opened new Exagen positions in Q4 2023 and 2 closed out, a net change of +1 holder.
  • The largest Exagen buyer in Q4 2023 was Perkins Capital Management, an estimated $424K added.
  • The largest Exagen seller in Q4 2023 was Stonepine Capital Management, an estimated $923K sold.

Based on aggregated 13F filings for Q4 2023.